Brett Dovman represents both public and privately held companies in a wide range of corporate and securities matters, including private financings, M&A, public offerings and corporate governance matters.
Cooley advised Ambrx Biopharma on its $126 million initial public offering of 7,000,000 American depositary shares, each representing seven ordinary shares. Ambrx Biopharma, whose securities now trade on the New York Stock Exchange under the symbol AMAM, is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop engineered precision biologics. Partners Charlie Kim, Patrick Loofbourrow, Sean Clayton and Will Cai led the Cooley team.
MannKind – $200 Million Convertible Notes Offering
March 2, 2021
Cooley advised MannKind on its offering of $200 million principal amount of 2.50% convertible senior notes due 2026. MannKind, whose securities trade on the Nasdaq Global Market under the symbol MNKD, focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Partners Sean Clayton, Mischi a Marca and Jason Savich led the Cooley team.
Cooley advised Silverback Therapeutics on its $277.7 million initial public offering of 13,225,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Silverback Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol SBTX, is a biopharmaceutical company that develops proprietary ImmunoTAC therapies targeting previously inaccessible disease pathways. Partners Ken Rollins and Charlie Kim led the Cooley team.
Cooley advised Kronos Bio on its $287.5 million initial public offering of 15,131,579 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Kronos Bio, whose securities now trade on the Nasdaq Global Select Market under the symbol KRON, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. Partners Charles Bair, Charlie Kim and Chad Mills led the Cooley team.